FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W44598650> ?p ?o ?g. }

• W44598650 endingPage "843" @default.
• W44598650 startingPage "830" @default.
• W44598650 abstract "// Håkon Reikvam 1,2 , Ina Nepstad 1 , Øystein Bruserud 1,2 , Kimberley Joanne Hatfield 1,2 1 Section for Hematology, Department of Clinical Science, University of Bergen, Norway 2 Department of Medicine, Haukeland University Hospital, Bergen, Norway. Correspondence: Øystein Bruserud, email: // Keywords : Acute myeloid leukemia, cytokines, mTOR, PI3K, Angiogenesis, Bone marrow microenvironment, Pharmacological intervention Received : April 10, 2013, Accepted : May 10, 2013, Published : May 11, 2013 Abstract Acute myeloid leukemia (AML) is a heterogeneous and aggressive malignancy with poor overall survival. Constitutive as well as cytokine-initiated activation of PI3K/Akt/mTOR signaling is a common feature of AML patients, and inhibition of this pathway is considered as a possible therapeutic strategy in AML. Human AML cells and different stromal cell populations were cultured under highly standardized in vitro conditions. We investigated the effects of mTOR inhibitors (rapamycin and temsirolimus) and PI3K inhibitors (GDC-0941 and 3-methyladenin (3-MA)) on cell proliferation and the constitutive release of angioregulatory mediators by AML and stromal cells. Primary human AML cells were heterogeneous, though most patients showed high CXCL8 levels and detectable release of CXCL10, Ang-1, HGF and MMP-9. Hierarchical clustering analysis showed that disruption of PI3K/Akt/mTOR pathways decreased AML cell release of CXCL8-11 for a large subset of patients, whereas the effects on other mediators were divergent. Various stromal cells (endothelial cells, fibroblasts, cells with osteoblastic phenotype) also showed constitutive release of angioregulatory mediators, and inhibitors of both the PI3K and mTOR pathway had anti-proliferative effects on stromal cells and resulted in decreased release of these angioregulatory mediators. PI3K and mTOR inhibitors can decrease constitutive cytokine release both by AML and stromal cells, suggesting potential direct and indirect antileukemic effects." @default.
• W44598650 created "2016-06-24" @default.
• W44598650 creator A5021294750 @default.
• W44598650 creator A5028830320 @default.
• W44598650 creator A5063670142 @default.
• W44598650 creator A5074974438 @default.
• W44598650 date "2013-05-11" @default.
• W44598650 modified "2023-10-03" @default.
• W44598650 title "Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells" @default.
• W44598650 cites W1495123612 @default.
• W44598650 cites W1559434684 @default.
• W44598650 cites W1567091232 @default.
• W44598650 cites W1614353414 @default.
• W44598650 cites W1934530049 @default.
• W44598650 cites W1970379448 @default.
• W44598650 cites W1970550717 @default.
• W44598650 cites W1974888028 @default.
• W44598650 cites W1977229123 @default.
• W44598650 cites W1983636872 @default.
• W44598650 cites W1983698019 @default.
• W44598650 cites W1987566410 @default.
• W44598650 cites W2011768640 @default.
• W44598650 cites W2013003434 @default.
• W44598650 cites W2013647024 @default.
• W44598650 cites W2013875870 @default.
• W44598650 cites W2015174126 @default.
• W44598650 cites W2021932312 @default.
• W44598650 cites W2028034052 @default.
• W44598650 cites W2032524481 @default.
• W44598650 cites W2036180243 @default.
• W44598650 cites W2041193952 @default.
• W44598650 cites W2049246619 @default.
• W44598650 cites W2051255344 @default.
• W44598650 cites W2058188568 @default.
• W44598650 cites W2080273279 @default.
• W44598650 cites W2088965961 @default.
• W44598650 cites W2089030718 @default.
• W44598650 cites W2089749985 @default.
• W44598650 cites W2094704733 @default.
• W44598650 cites W2096637671 @default.
• W44598650 cites W2101206043 @default.
• W44598650 cites W2102036384 @default.
• W44598650 cites W2105999965 @default.
• W44598650 cites W2110259614 @default.
• W44598650 cites W2111025081 @default.
• W44598650 cites W2112998845 @default.
• W44598650 cites W2116505368 @default.
• W44598650 cites W2121190158 @default.
• W44598650 cites W2123155231 @default.
• W44598650 cites W2125816527 @default.
• W44598650 cites W2129884547 @default.
• W44598650 cites W2131888987 @default.
• W44598650 cites W2138620207 @default.
• W44598650 cites W2141729412 @default.
• W44598650 cites W2146960590 @default.
• W44598650 cites W2147066718 @default.
• W44598650 cites W2147649894 @default.
• W44598650 cites W2157782360 @default.
• W44598650 cites W2161574806 @default.
• W44598650 cites W2163841494 @default.
• W44598650 cites W2169771822 @default.
• W44598650 cites W4253859745 @default.
• W44598650 doi "https://doi.org/10.18632/oncotarget.971" @default.
• W44598650 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3757241" @default.
• W44598650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23919981" @default.
• W44598650 hasPublicationYear "2013" @default.
• W44598650 type Work @default.
• W44598650 sameAs 44598650 @default.
• W44598650 citedByCount "43" @default.
• W44598650 countsByYear W445986502013 @default.
• W44598650 countsByYear W445986502014 @default.
• W44598650 countsByYear W445986502015 @default.
• W44598650 countsByYear W445986502016 @default.
• W44598650 countsByYear W445986502017 @default.
• W44598650 countsByYear W445986502018 @default.
• W44598650 countsByYear W445986502019 @default.
• W44598650 countsByYear W445986502020 @default.
• W44598650 countsByYear W445986502021 @default.
• W44598650 countsByYear W445986502022 @default.
• W44598650 crossrefType "journal-article" @default.
• W44598650 hasAuthorship W44598650A5021294750 @default.
• W44598650 hasAuthorship W44598650A5028830320 @default.
• W44598650 hasAuthorship W44598650A5063670142 @default.
• W44598650 hasAuthorship W44598650A5074974438 @default.
• W44598650 hasBestOaLocation W445986501 @default.
• W44598650 hasConcept C16930146 @default.
• W44598650 hasConcept C203014093 @default.
• W44598650 hasConcept C2778461978 @default.
• W44598650 hasConcept C2778690821 @default.
• W44598650 hasConcept C2778729363 @default.
• W44598650 hasConcept C2780394083 @default.
• W44598650 hasConcept C502942594 @default.
• W44598650 hasConcept C62478195 @default.
• W44598650 hasConcept C71924100 @default.
• W44598650 hasConcept C75217442 @default.
• W44598650 hasConcept C86554907 @default.
• W44598650 hasConcept C86803240 @default.
• W44598650 hasConcept C95444343 @default.

• next